EN DE

Genomma Lab Internacional S.A.B. de C.V (LABB) Fair Value & Analysis

Healthcare · MX · Market cap 14.7B MXN (≈ $867M) · ISIN MX01LA010006

GL Genomma Lab Internacional S.A.B. de C.V LABB · MX
Price13.50 MXN
Fair Value36.32 MXN
Upside+169.0%
Quality61/100
Watch Genomma Lab Internacional S.A.B. de C.V for free, get notified when fair value or trend changes. Watch for free

Strengths

✓Trades 63% below our fair value of 36.32 MXN
✓Low debt · generates free cash flow
✓Ranks above peers (13/15)

Risks

!Mixed Growth (revenue 5y +4.8 %/yr)
!Thin margins · 9.3% net margin
!Moderate moat 59/100
!Evidence only low, so the estimate is less certain
Mixed Growth (revenue 5y +4.8 %/yr)
Thin margins · 9.3% net margin
Low debt · generates free cash flow
5.93% dividend yield
Ranks above peers (13/15)
Moderate moat 59/100
Evidence: Low Range 23.69 MXN – 45.39 MXN Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 17 days ago

Share price −9.7% over the past month.

A solid business, trading 63% below our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Track Genomma Lab Internacional S.A.B. de C.V and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card. Track it free

What matters now

  • The price is below even our cautious bear case (23.69 MXN). The market is more pessimistic than our downside scenario.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (23.69 MXN to 45.39 MXN) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

27.09 MXN 10.70 MXN Fair Value 36.32 MXN May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 10.70 MXN – 27.09 MXN · fair‑value band 23.69 MXN – 45.39 MXN · the 13.50 MXN price screens below the 36.32 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Genomma Lab Internacional S.A.B. de C.V (LABB) currently trades at 13.50 MXN, while our model-based Fair Value estimate is 36.32 MXN, implying the stock looks roughly 169.0% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, Genomma Lab Internacional S.A.B. de C.V generated revenue of 17.3B MXN at a net margin of 9.3%. Revenue declined 4.9% year over year. It earns a return on equity of 14.1%. Net debt stands at 1.7B MXN. Fundamentals as of Aug 13, 2026

Our scenario range runs from 23.69 MXN (bear case) to 45.39 MXN (bull case); at 13.50 MXN, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -45% fair-value upside, at 169%, LABB screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.57 MXN per share, which is 1.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence 22.92 MXN 38.80 MXN 64.23 MXN 78
Growth DCF 23.12 MXN 38.64 MXN 63.37 MXN 76
Owner Earnings 22.17 MXN 37.57 MXN 62.23 MXN 74
All 26 models by family
DCF Models
FCF DCF best evidence 22.92 MXN 38.80 MXN 64.23 MXN 78
Owner Earnings 22.17 MXN 37.57 MXN 62.23 MXN 74
5Y Revenue Exit 28.95 MXN 51.12 MXN 80.30 MXN 71
5Y EBITDA Exit 33.09 MXN 59.16 MXN 90.55 MXN 74
5Y P/E Exit 22.85 MXN 39.30 MXN 57.07 MXN 70
10Y Revenue Exit 25.47 MXN 45.46 MXN 74.06 MXN 65
10Y EBITDA Exit 29.27 MXN 51.16 MXN 82.15 MXN 67
10Y P/E Exit 22.64 MXN 37.10 MXN 55.72 MXN 63
Earnings-Based
Graham-Dodd 11.22 MXN 41.13 MXN 55.52 MXN 64
Lynch FV 9.81 MXN 14.01 MXN 18.22 MXN 61
PEG = 1.0 9.81 MXN 14.01 MXN 18.22 MXN 57
EPV 26.40 MXN 31.09 MXN 35.20 MXN 74
Dividend Discount
Gordon GGM 7.34 MXN 15.26 MXN 24.22 MXN 66
DDM Multi-Stage 7.34 MXN 12.87 MXN 16.02 MXN 66
Multiples
P/E Multiple 27.24 MXN 36.32 MXN 45.39 MXN 63
P/S Multiple 21.05 MXN 28.06 MXN 35.08 MXN 58
P/B Multiple 21.05 MXN 28.06 MXN 35.08 MXN 55
EV/EBIT 47.25 MXN 63.58 MXN 79.90 MXN 66
EV/EBITDA 42.68 MXN 57.48 MXN 72.28 MXN 67
EV/Revenue 33.23 MXN 48.21 MXN 63.19 MXN 53
Asset-Based
NCAV (Graham) 5.68 MXN 7.61 MXN 11.36 MXN 54
Growth DCF
Growth DCF 23.12 MXN 38.64 MXN 63.37 MXN 76
Rev-Margin DCF 28.95 MXN 50.70 MXN 76.77 MXN 71
Economic Profit
Residual Income 11.23 MXN 14.20 MXN 32.65 MXN 70
ROIC Compounder 29.18 MXN 38.33 MXN 49.55 MXN 72
Growth Earnings
Growth-Adj P/E 18.96 MXN 27.08 MXN 35.21 MXN 67

Widest divergence: DCF Models (39.30 MXN) versus Asset-Based (7.61 MXN). Highest evidence: FCF DCF (78).

Notify me when LABB reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 8.2
P/S ratio 0.75 P/E × margin
EPS (TTM) 1.65 MXN price ÷ EPS = P/E 8.2
Dividend yield 5.9% payout 48.5%
Net margin 9.2% FY2025
Return on equity 14.1% TTM
More key figures
Profitability
Return on assets (EBIT) 15.3% avg 5y
Operating margin 20.9% TTM
Growth
Revenue (TTM) 17.3B MXN TTM
Revenue growth (YoY) -4.9% 3y avg +1.4%
Balance sheet & cash flow
Free cash flow 2.0B MXN FY2025
Net debt 1.7B MXN FY2025 · ≈ 0.8 yrs of FCF

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 61 · Market factors (momentum, volatility) 31

Profitability 57
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 64
Earnings quality: real cash, not paper profit
Fin. Strength 61
Balance sheet, leverage, solvency risk
Investment 89
Disciplined investing over empire-building
Low Volatility 79
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 62
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally.

Full company description

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Genomma Lab Internacional S.A.B. de C.V reported revenue of 17.5B MXN in FY2025 versus 15.5B MXN in FY2021, a compound +3.2%/yr. Reported net income was 1.6B MXN in FY2025, compounding +5.4%/yr from FY2021.

Growth Quality 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
17.5B MXN
Latest YoY
−5.7%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.4%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.8%
Avg. revenue growth/yr (20Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+17.5%
Value creation/yr (5Y, in MXN) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in MXN: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.7% (4.8 + 5.9)
Revenue +3.2%/yr
FY21 15.5B MXN
FY22 16.8B MXN
FY23 16.5B MXN
FY24 18.6B MXN
FY25 17.5B MXN
Net income +5.4%/yr
FY21 1.3B MXN
FY22 1.4B MXN
FY23 1.0B MXN
FY24 1.5B MXN
FY25 1.6B MXN

Watch LABB: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genomma Lab Internacional S.A.B. de C.V · Fair Value
36.32 MXN +63%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Genomma Lab Internacional S.A.B. de C.V Fair Value". https://www.fairvalue-calculator.com/stock/LABB

Peer Group

Drug Manufacturers - Specialty & Generic · 637 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 61 · Above median
Fair Value upside +169% · Top 25%
Return on equity (TTM) 14% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 9% · Above median
Operating margin (TTM) 21% · Top 25%
Revenue growth -5% · Below median
Dividend yield (TTM) 5.9% · Top 25%
Debt / equity 0.43× · Higher than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 8.2× · Cheaper than 75% of peers
P/B 1.33× · Cheaper than median
P/S (TTM) 0.85× · Cheaper than median
P/FCF 0.4× · Cheaper than 75% of peers
EV/EBITDA 4.1× · Cheaper than 75% of peers
PEG 0.86× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE100 · sector 4
FUTURE0 · sector 21
PAST56 · sector 23
HEALTH79 · sector 97
DIVIDEND100 · sector 29

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €140.25 €106.48 -24%
Takeda Pharmaceutical Company TAK $18.03 $11.11 -38%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Galderma Group GALD CHF 178.55 CHF 55.07 -69%
Haleon plc HLN $10.11 $7.64 -24%
Teva Pharmaceutical Industries Limited TEVA $37.92 $15.33 -60%
Sandoz Group SDZ CHF 70.66 CHF 39.21 -45%
Zoetis Inc ZTS $77.52 $104.88 +35%
Hansoh Pharmaceutical Group 3692 HK$33.50 HK$16.14 -52%

Compare Genomma Lab Internacional S.A.B. de C.V with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Genomma Lab Internacional S.A.B. de C.V (LABB) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 36.32 MXN versus a price of 13.50 MXN, about +169% (undervalued).
What is the fair value of LABB?
Our model-based fair value for Genomma Lab Internacional S.A.B. de C.V is 36.32 MXN (as of Aug 13, 2026), built from audited fundamentals. The current price: 13.50 MXN.
What is the quality score of LABB?
Genomma Lab Internacional S.A.B. de C.V has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Genomma Lab Internacional S.A.B. de C.V (LABB)?
Genomma Lab Internacional S.A.B. de C.V reported trailing-twelve-month revenue of about 17.3B MXN (latest available figure, as of Aug 13, 2026).
What is the net profit margin of LABB?
The net profit margin of Genomma Lab Internacional S.A.B. de C.V is about 9.3%, meaning it keeps roughly 9.3% of revenue as net income. Based on the latest reported figures.
Does Genomma Lab Internacional S.A.B. de C.V pay a dividend?
Genomma Lab Internacional S.A.B. de C.V currently shows a dividend yield of about 5.93% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free · no account needed

Watch Genomma Lab Internacional S.A.B. de C.V in the live analysis

One click puts Genomma Lab Internacional S.A.B. de C.V on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.